<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer

<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer have?

<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer has 138 citations in the OpenAlex counts ScholarIQ stores.

When was <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer published?

<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer has 2018 year in the ScholarIQ index.

What is the open-access status of <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer?

<i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer has bronze oa status in the ScholarIQ index.

What is the DOI of <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer?

The DOI for <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer is on the source record.

What is the PMID of <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer?

The PMID for <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer is on the source record.

What is the OpenAlex record for <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer?

The OpenAlex for <i>EML4‐ALK</i> fusion variant V3 is a high‐risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK⁺ non‐small cell lung cancer is on the source record.